Soluble DNAM-1, as a predictive biomarker for acute Graft-Versus-Host disease

14Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

Abstract

Acute graft-versus-host disease (aGVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Because diagnosis of aGVHD is exclusively based on clinical symptoms and pathological findings, reliable and noninvasive laboratory tests for accurate diagnosis are required. An activating immunoreceptor, DNAM-1 (CD226), is expressed on T cells and natural killer cells and is involved in the development of aGVHD. Here, we identified a soluble form of DNAM-1 (sDNAM-1) in human sera. In retrospective univariate and multivariate analyses of allo-HSCT patients (n = 71) at a single center, cumulative incidences of all grade (grade I-IV) and sgrade II-IV aGVHD in patients with high maximal serum levels of sDNAM-1 (≥30 pM) in the 7 days before allo-HSCT were significantly higher than those in patients with low maximal serum levels of sDNAM-1 (<30 pM) in the same period. However, sDNAM-1 was not associated with other known allo-HSCT complications. Our data suggest that sDNAM-1 is potentially a unique candidate as a predictive biomarker for the development of aGVHD.

Cite

CITATION STYLE

APA

Kanaya, M., Shibuya, K., Hirochika, R., Kanemoto, M., Ohashi, K., Okada, M., … Shibuya, A. (2016). Soluble DNAM-1, as a predictive biomarker for acute Graft-Versus-Host disease. PLoS ONE, 11(6). https://doi.org/10.1371/journal.pone.0154173

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free